《阿斯利康AstraZeneca（AZN）2025年第三季度及9M投资者和分析师财报电话会议纪要PPT「LSE」（英文版）（39页）.pdf》由会员分享，可在线阅读，更多相关《阿斯利康AstraZeneca（AZN）2025年第三季度及9M投资者和分析师财报电话会议纪要PPT「LSE」（英文版）（39页）.pdf（39页珍藏版）》请在三个皮匠报告上搜索。

1、9M and Q3 2025 ResultsConference call and webcast for investors and analysts 6 November 20252Cautionary statements regarding forward-looking statementsIn order,among other things,to utilise the safe harbour provisions of the US Private Securities Litigation Reform Act of 1995,AstraZeneca(hereafter t

2、he Group)provides the following cautionary statement:This document contains certain forward-looking statements with respect to the operations,performance and financial condition of the Group,including,among other things,statements about expected revenues,margins,earnings per share or other financial

3、 or other measures.Although the Group believes its expectations are based on reasonable assumptions,any forward-looking statements,by their very nature,involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those

4、predicted.The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements.The Group identifies the forward-looking statements by using the words anticipates,believ

5、es,expects,intends and similar expressions in such statements.Important factors that could cause actual results to differ materially from those contained in forward-looking statements,certain of which are beyond the Groups control,include,among other things:the risk of failure or delay in delivery o

6、f pipeline or launch of new medicines;the risk of failure to meet regulatory or ethical requirements for medicine development or approval;the risk of failures or delays in the quality or execution of the Groups commercial strategies;the risk of pricing,affordability,access and competitive pressures;